Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (DE:74D)
FRANKFURT:74D
RESEARCH TOOLSreports
Holding DE:74D?
Track your performance easily
74D Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.95 - €3.42
Previous Close€2.22
Volume0.00
Average Volume (3M)N/A
Market Cap
€78.60M
Enterprise Value€126.95M
Total Cash (Recent Filing)$32.52M
Total Debt (Recent Filing)$85.11M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Mar 13, 2025EPS Estimate
-€0.1Last Dividend Ex-Date
Apr 27, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding31,793,047
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.85
Price to Sales (P/S)1.36
Price to Cash Flow (P/CF)7.90
P/FCF Ratio1.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit2.29
Enterprise Value/Ebitda7.52
Forecast
1Y Price Target
€4.26Price Target Upside92.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
HLS Therapeutics Inc News
PremiumCompany Announcements
HLS Therapeutics to Announce Q3 2024 Financial Results
PremiumCompany Announcements
HLS Therapeutics to Present at Global Investment Conference
PremiumCompany Announcements
HLS Therapeutics Reports Mixed Q2 Results and Strategic SalesPremiumCompany Announcements
HLS Therapeutics Expands Vascepa Coverage in Canada
PremiumCompany Announcements
HLS Therapeutics Schedules Q2 Financial Results Call
PremiumCompany Announcements
HLS Therapeutics Divests Royalty Interest, Updates GuidancePremiumCompany Announcements
HLS Therapeutics Shareholders Back Board and Auditors
PremiumCompany Announcements
HLS Therapeutics Boosts Treatment Adherence with Support ProgramsBulls Say, Bears Say
Bulls Say
Future ObligationsDRI also assumed $18.5 million of potential future milestone payment obligations for which HLS would have been on the hook.
Strategic SaleHLS announced the sale of its Xenpozyme royalty to DRI Healthcare Trust.
Upfront PaymentDRI paid $13.25M upfront with $14.0M in sales-based milestones potentially payable to HLS.
Bears Say
Earnings2Q-2024 revenues were down 12% vs 2Q-2023.
Financial Performance2024 revenue guidance was reduced to $60-$62M from previously $63.5-$66.5 million.
Operational ChangesThe company announced it is terminating its Vascepa primary care promotional activities.
---
Options Prices
Currently, No data available
---
Ownership Overview
20.10% Insiders
0.01% Mutual Funds
1.57% Other Institutional Investors
78.32% Public Companies and
Individual Investors
74D FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was €1.95 and its highest was €3.42 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
Currently, no data Available
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 124 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -€0.138 earnings per share for the quarter, missing the consensus estimate of -€0.115 by -€0.023.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of €0.03 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -€0.1.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 31,793,047 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -€0.138 in its last earnings report, missing expectations of -€0.115. Following the earnings report the stock price went up 2.778%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:74D
---
HLS Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.26 (92.03% Upside)
€4.26 (92.03% Upside)
Insider Transactions
Bought Shares
Worth C$12.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.71%
12-Months-Change
Fundamentals
Return on Equity
-24.49%
Trailing 12-Months
Asset Growth
-20.27%
Trailing 12-Months
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.
---
74D Stock 12 Month Forecast
Average Price Target
€4.26
▲(92.03% Upside)
Technical Analysis
Best Analysts Covering 74D
1 Year
1 Year Success Rate
11/31 ratings generated profit
1 Year Average Return
+6.87%
reiterated a buy rating 3 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 35.48% of your transactions generating a profit, with an average return of +6.87% per trade.
---